MarketLens

Pricing Plans Sign Up Log in

Stock Analysis Investment Ideas Pro

Is Collegium Pharmaceutical's Diversification Strategy Paying Off

4 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Is Capital One's Bold Acquisition Strategy Paying Off

4 months ago

Is WildBrain's Strategic Pivot Paying Off

1 months ago

Is Hut 8's Strategic Pivot to AI Infrastructure Paying Off

2 months ago

Is LGI Homes' Aggressive Expansion Strategy Paying Off

2 months ago

Collegium Pharmaceutical Stock Gains 12% in Three Months: Here's Why

Collegium Pharmaceutical stock rose 12% in three months, after strong Jornay PM growth and the Azstarys acquisition boosted 2026 guidance, strengthening its ADHD franchise and revenue outlook.

COLL

Stock News•4 weeks ago

Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?

Alnylam's revenue diversification from Givlaari, Oxlumo, and Leqvio could reduce reliance on Amvuttra, the primary growth driver.

ALNY

Stock News•2 months ago

Is CAH Becoming the Backbone of US Healthcare Infrastructure?

Cardinal Health is diversifying its business model by expanding into specialty care, logistics, and nuclear medicine. This strategic shift aims to deepen the company's role within the broader US healt...

CAH

Stock News•2 months ago

Pacira BioSciences: Exparel Still Supports My Original Bull Case

Pacira BioSciences remains heavily reliant on its flagship non-opioid pain product, Exparel, to drive commercial performance. Future valuation will likely hinge on the company's 2026 pipeline readouts...

PCRX